Research programme: autism and obesity therapeutics - Berand Neuropharmacology
Latest Information Update: 16 Jul 2016
At a glance
- Originator Berand Neuropharmacology
- Class
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autistic disorder; Obesity
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autistic-disorder in Ireland
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in Ireland
- 19 Nov 2008 Preclinical trials in Autism in Ireland (unspecified route)